Natco Pharma logo

Natco Pharma results

NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap

Last close ₹791.85up ₹6.70 (0.85%)BSE ₹792.20

Share price at the NSE close on 23 Oct 2026. Previous close ₹785.15.

52-week range of traded prices to 23 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
Market cap
₹15,534 Cr380th largest listed
P/E
13.6
P/B
Shares changed
Dividend yield
0.57%
ROE
13.6%
ROCE
8.6%
Debt to equity
0.08
Volume, NSE
5,69,53550.8% delivered

Q1 results, quarter to Jun 2026

Consolidated: the company and its subsidiaries together. ₹ crore.Natco Pharma annual results and balance sheet

Revenue
₹735 Cr−44.7% on a year ago · −0.5% on the quarter before
Operating profit
₹187 Cr−67.3% on a year ago · +46.2% on the quarter before
Net profit
₹207 Cr−57.0% on a year ago · −23.2% on the quarter before
Earnings per share
₹11.53−57.0% on a year ago · −22.9% on the quarter before
Operating margin
25.4%
Net margin
28.1%

From revenue to net profit, ₹ crore

  1. Revenue735
  2. Materials and goods−148
  3. Employee costs−179
  4. Other expenses−222
  5. Operating profit187
  6. Depreciation−47
  7. Other income+59
  8. Finance costs−13
  9. Profit before tax186
  10. Tax−63
  11. Joint ventures+84
  12. Net profit207

Natco Pharma results by quarter

Consolidated: the company and its subsidiaries together. Latest quarter to Jun 2026. Results for the quarter to Sep 2026 are due by 14 Nov 2026, 45 days after it ends.Results filings and date

Revenue and net profit by quarter, ₹ crore

  • Revenue
  • Net profit

Operating and net margin by quarter, per cent

  • Operating margin
  • Net margin
₹ croreSep 2021Q2Filed 11 NovDec 2021Q3Filed 14 FebMar 2022Q4Filed 31 MayJun 2022Q1Filed 10 AugSep 2022Q2Filed 10 NovDec 2022Q3Filed 9 FebMar 2023Q4Filed 29 MayJun 2023Q1Filed 9 AugSep 2023Q2Filed 15 NovDec 2023Q3Filed 15 FebMar 2024Q4Filed 27 MayJun 2024Q1Filed 13 AugSep 2024Q2Filed 12 NovDec 2024Q3Filed 12 FebMar 2025Q4Filed 12 JunJun 2025Q1Filed 12 AugSep 2025Q2Filed 14 NovDec 2025Q3Filed 12 FebMar 2026Q4Filed 29 MayJun 2026Q1Filed 14 Aug
Revenue from operations3775615978854324938981,1411,0317591,0681,3631,3714751,2211,3291,363647739735
307459615489337387559613573491571558567436673758784489612549
Materials and goods bought939329614810611525819621616214318017883249233170133155148
Employee costs109118109152110106119138122122143142152142159169200159159179
Other expenses105248210190121166182278235206286236238212264356414196298222
Operating profit before depreciation71102−193959510633952845826849780580439548571579159128187
Operating margin18.7%18.2%−3.1%44.7%22.1%21.5%37.8%46.3%44.4%35.3%46.6%59.1%58.7%8.2%44.9%43.0%42.5%24.5%17.3%25.4%
Depreciation and amortisation3536384042424144444456444647985852465047
Other income383014342121292029374248641766662100587859
Finance costs4574443445654410313101113
One-off items00000000000000000000
Profit before tax7091−503867081324500440256478804818164506572614161144186
5111651419498071449113514231100929621−8963
Tax rate6.7%11.6%–17.0%19.2%23.5%15.0%15.9%16.1%17.0%19.1%16.8%17.3%19.1%19.7%16.0%15.6%12.8%−61.9%34.2%
Share of profit of joint ventures and associates–––––––––––––––––113684
6580−513205762276420369213386669677132406480518151269207
Other comprehensive income−72822−2−48014−518−13−1419−11−18394012583111
Total comprehensive income58108−293185371276435364231374654696122388520558276352318
Net margin17.3%14.3%−8.5%36.2%13.1%12.6%30.7%36.9%35.8%28.0%36.2%49.1%49.3%27.9%33.3%36.1%38.0%23.4%36.4%28.1%
Net margin without joint ventures and associates–––––––––––––––––21.7%31.6%16.6%
Earnings per share₹3.57₹4.41−₹2.77₹17.55₹3.11₹3.41₹15.11₹23.26₹20.60₹11.88₹21.56₹37.32₹37.81₹7.43₹22.70₹26.84₹28.94₹8.46₹14.96₹11.53
Diluted earnings per share₹3.57₹4.40−₹2.77₹17.55₹3.11₹3.41₹15.11₹23.26₹20.60₹11.88₹21.56₹37.32₹37.81₹7.43₹22.70₹26.84₹28.94₹8.46₹14.96₹11.53
Earnings per share in rupees, restated for later splits and bonuses.

Filed results, as an XML file each

16 earlier filings

Segment results by quarter

Consolidated, ₹ crore, quarters to Jun 2026.Natco Pharma segment results by year

  • Pharmaceuticals

    Revenue, ₹ crore
    Profit, ₹ crore
  • Agro Chemicals

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue of all businesses1,0317591,0751,3631,3714751,2211,3291,363647739735
Company revenue, as in its results1,0317591,0681,3631,3714751,2211,3291,363647739735
Revenue9807451,0751,3471,3564601,2061,2941,311619717694
Revenue growth128.3%54.3%23.4%23.4%38.4%−38.3%12.2%−3.9%−3.4%34.6%−40.6%−46.3%
Profit440276537829846189597578633180155204
Profit growth483.2%208.6%64.1%65.8%92.4%−31.4%11.2%−30.2%−25.1%−4.9%−74.0%−64.7%
Margin44.9%37.1%50.0%61.5%62.4%41.2%49.5%44.7%48.3%29.1%21.7%29.4%
Assets5,3735,3734,5654,8885,1304,4025,3995,4635,8737,3639,6769,900
Liabilities6377015816157075686327401,2781,5241,4911,486
Capital employed4,7364,6723,9844,2734,4223,8344,7674,7234,5955,8398,1858,415
Revenue5214−6161515153553282341
Profit is before tax and finance costs, the way companies report their segments.